ArticleJournal of nanobiotechnology2025
Exploring the multi-repair effects of advanced biomimetic rapamycin nanoparticles on cerebral ischemia-reperfusion injury.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ischemic stroke, an intractable neurovascular disease with high lethality, disability and recurrence rates, poses a serious challenge to human health. The only effective treatment for acute stroke is reperfusion therapy. However, the inflammatory response caused by reperfusion therapy often aggravates secondary brain tissue damage, which greatly affects the treatment effect. Currently, therapeutic options for reperfusion injury remain unsatisfactory, and neuroprotective options are lacking. The inhibition of microglia polarization and promotion of neovascular maturation are essential for reestablishing the integrity of the BBB. Specifically, McM/RNPs effectively inhibited the secretion of pro-inflammatory factors such as tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and promoted the release of anti-inflammatory and neuroprotective factors such as interleukin-10 (IL-10), vascular endothelial growth factor-A (VEGF-A), and brain-derived neurotrophic factor (BDNF). This effect not only alleviated the inflammatory response but also promoted the expression of endothelial tight junction proteins (such as ZO-1 and Claudin 5), thereby enhancing the integrity of the BBB. Furthermore, McM/RNPs exerted multiple effects, such as promoting neuronal survival, regulating pericyte function, and accelerating the maturation of the neovasculature, which are essential for repairing the damaged BBB. Through the multi-functional effects of anti-inflammation, anti-apoptosis and pericyte regulation, the McM/RNPs nanosystem successfully maintained the stability of the intracerebral environment, providing novel ideas and strategies for the clinical treatment of reperfusion injury in ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.